Avivagen has been analyzing opportunities to combine their propietary product OxC-betaTM with licensed cannabis products and they believe there are various combinations that could result in new products for the company. For the full news release, click here.
“We are enthusiastic about working with leading edge cannabis companies and participating in their development of a line of products which incorporate our unique OxC-beta™ technology,” says Kym Anthony, Chairman and Interim CEO, Avivagen. “We have been vocal advocates for the benefits of new product categories and look forward to collaborating with these large, well-resourced and innovative companies to bring these innovative products to the worldwide market, where appropriate.”
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com.